CEO Alex H. has a problem. He was planted by Roche to help acquire cheaply BioMarin for its rare diseases and gene therapy business. Now Roche has lost interest in these parts of BioMarin portfolio. Meantime Alex hired senior team members to conduct the M&A process and prepared ground by streamlining the company thru layoffs. At the same time, the action was taken to lower the company stock price. Since Roche lost interest current interest should be opposite, eg. to increase the company value. This can be done by careful layoffs and pruning the incompetent and redundant or unnecessary management, for example, the Business Development VP, Chief Technology Officer VP, Technical Development VP, Or R&D Enzymes VP. Some cancelled future projects may be reconsidered in this new landscape. Question is whether Alex H is capable to bring back the company on the track considering his past experience at Genentech?
layoff of 72, a small number comparing to company size, but be one of these.
Another proof how incompetent the pharma management is. Strategy, what strategy? Firstly they create a hype, hire many and then, oops!
MariTide and bone loss:
Get ready for purge, there is additional excuse.
Although it was "only" Level 1 trials.
Amgen never misses opportunity to purge ranks, though.
New layoff lists are being prepared. Make sure you know whether your name is on a list. Also check who can be influential in this process and who is responsible for singling you out.
